Merck’s MMRV Vaccine Gets FDA Approval for Intramuscular Delivery

The US Food and Drug Administration (FDA) has cleared intramuscular administration for measles, mumps, rubella, and varicella (MMRV) vaccines from Merck. This opens up more options for care providers and marks a shift from subcutaneous injections, which were the standard for the shot. The approval covers three of Merck’s MMRV vaccines.

According to Emily Kimber, “The three vaccines included in Merck’s MMRV family – M-M-R II, Varivax and ProQuad – are now the only vaccines for MMRV approved to be administered intramuscularly in the US, having already been licensed for intramuscular administration in the EU.”

To read more, click here.

(Source: PM Live, March 7^th, 2023)